Treg/Th17、Th1/Th2平衡在自身免疫性肝炎中的免疫学机制及诊疗新靶点

王维钊; 向晓星

doi:10.3969/j.issn.1001-5256.2019.08.051

Treg/Th17、Th1/Th2平衡在自身免疫性肝炎中的免疫学机制及诊疗新靶点

DOI: 10.3969/j.issn.1001-5256.2019.08.051

大连医科大学消化内科
苏北人民医院扬州大学临床医学院消化内科

详细信息

中图分类号: R575.1
计量
- 文章访问数: 1597
- HTML全文浏览量: 52
- PDF下载量: 246
- 被引次数: 0
出版历程
- 收稿日期: 2019-02-26
- 出版日期: 2019-08-20

Immunological mechanism of Treg/Th17 and Th1/Th2 balance in autoimmune hepatitis and new targets for diagnosis and treatment

Department of Gastroenterology, Dalian Medical University

摘要

摘要: 自身免疫性肝炎(AIH)是一种发生在肝脏的慢性自身免疫性疾病,临床主要表现为自身抗体阳性,转氨酶异常升高,高丙种球蛋白血症。目前的研究显示,调节性T淋巴细胞(Treg)/辅助性T淋巴细胞(Th) 17、Th1/Th2失衡是AIH发生发展机制之一。而OX40与其配体OX40L是肿瘤坏死因子家族的成员,二者结合作为T淋巴细胞活化的协同性刺激因子参与免疫应答,能够调节Treg/Th17、Th1/Th2平衡,影响多种自身免疫性疾病进程。但目前其在AIH的研究鲜有报道。查阅相关文献,围绕Treg/Th17、Th1/Th2平衡在AIH中的作用及免疫诊疗新靶点OX40/OX40L与AIH的潜在关系作一综述。
- 肝炎,自身免疫性 /
- T淋巴细胞,调节性 /
- T淋巴细胞,辅助诱导
Abstract: Autoimmune hepatitis (AIH) is a chronic autoimmune disease in the liver, with major clinical manifestations of positive autoantibody, abnormal elevation of aminotransferases, and hypergammaglobulinemia. Current studies have shown that regulatory T (Treg) /T helper17 (Th17) and T helper 1 (Th1) /T helper 2 (Th2) imbalance is one of the mechanisms of the development and progression of AIH. OX40 (also known as CD134, TNFRSF4, or ACT35) and its ligand OX40 L are members of the tumor necrosis factor family, and they participate in immune response as co-stimulators of T cell activation and can regulate Treg/Th17 and Th1/Th2 balance, thus affecting the progression of various autoimmune diseases. However, there are few reports on the role of OX40 and OX40 L in AIH. With reference to related articles, this article reviews the role of Treg/Th17 and Th1/Th2 balance in AIH and the potential association between OX40/OX40 L (new targets for immunological diagnosis and treatment) and AIH.
- hepatitis, autoimmune /
- T-lymphocytes, regulatory /
- T-lymphocytes, helper-inducers

HTML全文

参考文献(39)

[1] FRKKILM. Autoimmune hepatitis[J]. Duodecim, 2013, 129 (17) :1764-1772.

[2] YANG F, WANG Q, BIAN Z, et al. Autoimmune hepatitis:East meets west[J]. J Gastroenterol Hepatol, 2015, 30 (8) :1230-1236.

[3] LIWINSKI T, SCHRAMM C. Autoimmune hepatitis-update on clinical management in 2017[J]. Clin Res Hepatol Gastroenterol, 2017, 41 (6) :617-625.

[4] WANG QX, YAN L, MA X, et al. J Autoimmune hepatitis in the Asia-Pacific area[J]. J Clin Transl Hepatol, 2018, 6 (1) :48-56.

[5] ARNDTZ K, HIRSCHFIELD GM. The pathogenesis of autoimmune liver disease[J]. Dig Dis, 2016, 34 (4) :327-333.

[6] WILLOUGHBY J, GRIFFITHS J, TEWS I, et al. OX40:Structure and function-What questions remain?[J]. Mol Immunol, 2017, 3 (83) :13-22.

[7] LIU Y, YAN W, YUAN W, et al. Treg/Th17 imbalance is associated with poor autoimmune hepatitis prognosis[J]. Clin Immunol, 2019, 198:79-88.

[8] LIANG M, LIWEN Z, YUN Z, et al. The imbalance between Foxp3 (+) Tregs and Th1/Th17/Th22 cells in patients with newly diagnosed autoimmune hepatitis[J]. Clin Immunol, 2018, 2018:3753081.

[9] WING JB, TANAKA A, SAKAGUCHI S, et al. Human FOXP3 (+) regulatory T cell heterogeneity and function in autoimmunity and cancer[J]. Immunity, 2019, 50 (2) :302-316.

[10] FRANTZ C, AUFFRAY C, AVOUAC J, et al. Regulatory T cells in systemic sclerosis[J]. Front Immunol, 2018, 9:2356.

[11] XU CT, ZHENG F, WANG RG, et al. Immunological changes of regulatory T cells during perioperative period in patients with cholangiolitic jaundice[J]. Clin J Med Offic, 2018, 46 (8) :865-868. (in Chinese) 许长涛, 郑方, 王瑞官, 等.胆管结石性黄疸患者围术期内调节性T细胞免疫功能变化临床研究[J].临床军医杂志, 2018, 46 (8) :865-868.

[12] PALOMARES O, MARTN-FONTECHA M, LAUENER R, et al. Regulatory T cells and immune regulation of allergic diseases:Roles of IL-10 and TGF-beta[J]. Genes Immun, 2014, 15 (8) :511-520.

[13] BOYMAN O, KOLIOS AG, RAEBER ME, et al. Modulation of T cell responses by IL-2 and IL-2 complexes[J]. Clin Exp Rheumatol, 2015, 33 (4 Suppl 92) :s54-s57.

[14] FASCHING P, STRADNER M, GRANINGER W, et al. Therapeutic potential of targeting the Th17/Treg axis in autoimmune disorders[J]. Molecules, 2017, 22 (1) :e134.

[15] GRANT CR, LIBERAL R, MIELI-VERGANI G, et al. Regulatory T-cells in autoimmune diseases:Challenges, controversies and—yet—unanswered questions[J]. Autoimmun Rev, 2015, 14 (2) :105-116.

[16] DIESTELHORST J, JUNGE N, SCHLUE J, et al. Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy[J]. PLo S One, 2017, 12 (7) :e0181107.

[17] TAUBERT R, HARDTKE-WOLENSKI M, NOYAN F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies[J].J Hepatol, 2014, 61 (5) :1106-1114.

[18] JIN Z, YOU J, WANG HT. The role of the balance between Th17 and Treg in liver disease[J]. Chin J Hepatol, 2017, 25 (8) :637-640. (in Chinese) 靳智, 游晶, 王宏图. Th17/Treg平衡在肝脏疾病中的作用[J].中华肝脏病杂志, 2017, 25 (8) :637-640.

[19] AN J. Expression and significance of Th17 cells and related factors in patients with autoimmune hepatitis[J]. Comb Chem High Throughput Screen, 2019.[Epub ahead of print]

[20] PATERSON DJ, JEFFERIES WA, GREEN JR, et al. Antigens of activated rat T lymphocytes including a molecule of 50, 000Mr detected only on CD4 positive T blasts[J]. Mol Immunol, 1987, 24 (12) :1281-1290.

[21] WEBB GJ, HIRSCHFIELD GM, LANE PJ, et al. OX40, OX40L and autoimmunity:A comprehensive review[J]. Clin Rev Allergy Immunol, 2016, 50 (3) :312-332.

[22] ZHANG X, XIAO X, LAN P, et al. OX40 costimulation inhibits Foxp3 expression and treg induction via BATF3-dependent and independent mechanisms[J]. Cell Rep, 2018, 24 (3) :607-618.

[23] JACQUEMIN C, AUGUSTO JF, SCHERLINGER M, et al.OX40L/OX40 axis impairs follicular and natural Treg function in human SLE[J]. JCI Insight, 2018, 3 (24) . pii:122167.

[24] VOO KS, BOVER L, HARLINE ML, et al. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function[J]. Immunol, 2013, 191 (7) :3641-3650.

[25] HUANG L, WANG M, YAN Y, et al. OX40L induces helper T cell differentiation during cell immunity of asthma through PI3K/AKT and P38 MAPK signaling pathway[J]. J Transl Med, 2018, 16 (1) :74.

[26] LEI W, ZENG DX, ZHU CH, et al. The upregulated expression of OX40/OX40L and their promotion of T cells proliferation in the murine model of asthma[J]. J Thorac Dis, 2014, 6 (7) :979-987.

[27] ZHANG Z, ZHONG W, HINRICHS D, et al. Activation of OX40augments Th17 cytokine expression and antigen-specific uveitis[J]. Am J Pathol, 2010, 177 (6) :2912-2920.

[28] SUN G, JIN H, ZHANG C, et al. OX40 Regulates both innate and adaptive immunity and promotes nonalcoholic steatohepatitis[J]. Cell Rep, 2018, 25 (13) :3786-3799.

[29] SITRIN J, SUTO E, WUSTER A, et al. The Ox40/Ox40 ligand pathway promotes pathogenic Th cell responses, plasmablast accumulation, and lupus nephritis in NZB/W F1 mice[J]. J Immunol, 2017, 199 (4) :1238-1249.

[30] AIZAWA Y, HOKARI A. Autoimmune hepatitis:Current challenges and future prospects[J]. Clin Exp Gastroenterol, 2017, 10:9-18.

[31] ZHANG Y, ZHANG Y, GU W, et al. TH1/TH2 cell differentiation and molecular signals[J]. Adv Exp Med Biol, 2014, 841:15-44.

[32] GANDHI GR, NETA MTSL, SATHIYABAMA RG, et al. Flavonoids as Th1/Th2 cytokines immunomodulators:A systematic review of studies on animal models[J]. Phytomedicine, 2018, 44:74-84.

[33] VINCZE K, KOLONICS-FARKAS A, BOHACS A, et al. Peripheral CD4+T-cell changes in connective tissue diseases[J]. Cytokine Growth Factor Rev, 2018, 43:16-24.

[34] BEHFARJAM F, SANATI MH, NASSERI MOGHADDAM S, et al. Role of Th1/Th2 cells and related cytokines in autoimmune hepatitis[J]. Turk J Gastroenterol, 2017, 28 (2) :110-114.

[35] WANG Q, SHI BM, XIE F, et al. Enhancement of CD4 (+) T cell response and survival via coexpressed OX40/OX40L in Graves’disease[J]. Mol Cell Endocrinol, 2016, 430:115-124.

[36] WU Q, TANG Y, HU X, et al. Regulation of Th1/Th2 balance through OX40/OX40L signalling by glycyrrhizic acid in a murine model of asthma[J]. Respirology, 2016, 21 (1) :102-111.

[37] UENO H, BLANCO P. OX40/OX40L axis:Not a friend in autoimmunity[J]. Oncotarget, 2015, 6 (26) :21779-21780.

[38] HALIM TYF, RANA BMJ, WALKER JA, et al. Tissue-restricted adaptive type 2 immunity is orchestrated by expression of the costimulatory molecule OX40L on group 2 innate lymphoid cells[J]. Immunity, 2018, 48 (6) :1195-1207.

[39] HIRAHARA K, NAKAYAMA T. CD4+T-cell subsets in inflammatory diseases:Beyond the Th1/Th2 paradigm[J]. Int Immunol, 2016, 28 (4) :163-171.

施引文献

资源附件(0)

访问统计